Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vistagen Therapeutics, Inc.VTGN · Entity 7955 | Chief Legal Officer | June 30, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vistagen Therapeutics, Inc.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,868 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 36,818 · Balance 60,868 F1: Represents acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended (the "ESPP"), in a transaction exempt under Rule 16b-3 and Rule 16b-3(d). The Reporting Person purchased the maximum amount permitted under the ESPP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended (the "ESPP"), in a transaction exempt under Rule 16b-3 and Rule 16b-3(d). The Reporting Person purchased the maximum amount permitted under the ESPP.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 2, 2026 20:34 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 36,818 | $0.19 | $7,072.74 |
DisclosureSEC source: 0001924908-26-000007 · form4-07022026_080703.xml · nonDerivative · entry 1 Adler Reid G. · CIK 0001924908 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,868 F1 · kind: Represents acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended (the "ESPP"), in a transaction exempt under Rule 16b-3 and Rule 16b-3(d). The Reporting Person purchased the maximum amount permitted under the ESPP. Read SEC document |
| April 07, 2026 Filed Apr 10, 2026 00:33 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 56,247 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001924908-26-000005 · edgardoc.xml · derivative · entry 2 Adler Reid G. · CIK 0001924908 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,247 Underlying: Common Stock · 56,247 shares Expires 2036-04-07 F1 · derivative.exercise_date: Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. 25% of the Options will vest on the six-month anniversary of April 7, 2026 (the "Grant Date"), and will vest in 25% installments every six months thereafter until the Options become fully vested on the two (2) year anniversary of the Grant Date. Read SEC document |
| April 07, 2026 Filed Apr 10, 2026 00:33 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantIncentive Stock Option (right to buy) · Derivative | 18,753 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001924908-26-000005 · edgardoc.xml · derivative · entry 1 Adler Reid G. · CIK 0001924908 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,753 Underlying: Common Stock · 18,753 shares Expires 2036-04-07 F1 · derivative.exercise_date: Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. 25% of the Options will vest on the six-month anniversary of April 7, 2026 (the "Grant Date"), and will vest in 25% installments every six months thereafter until the Options become fully vested on the two (2) year anniversary of the Grant Date. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 21:50 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 7,541 | $1.70 | $12,819.70 |
DisclosureSEC source: 0001415889-25-018755 · form4-07012025_090738.xml · nonDerivative · entry 1 Adler Reid G. · CIK 0001924908 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,050 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended, in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d). Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:15 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001415889-25-018201 · form4-06252025_050603.xml · derivative · entry 1 Adler Reid G. · CIK 0001924908 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-06-23 F1 · derivative.exercise_date: Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Equity Omnibus Incentive Plan, as amended. The Options will begin vesting on June 23, 2025 (the "Grant Date"), and will vest in equal monthly installments over a three-year period until the Options become fully vested on the three (3) year anniversary of the Grant Date. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 22:07 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 4,854 | $2.96 | $14,358.13 |
DisclosureSEC source: 0001415889-24-019022 · form4-07022024_100750.xml · nonDerivative · entry 1 Adler Reid G. · CIK 0001924908 · CHF CORP DEVEL OFF, GEN COUNS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,509 F1 · shares: Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended. Read SEC document |
| June 24, 2024 Filed Jun 27, 2024 01:30 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 170,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001415889-24-018278 · form4-06272024_010654.xml · derivative · entry 1 Adler Reid G. · CIK 0001924908 · CHF CORP DEVEL OFF, GEN COUNS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2034-06-24 F1 · derivative.exercise_date: Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Equity Omnibus Incentive Plan, as amended. The Options will begin vesting on June 24, 2024 (the "Vesting Start Date"), and will vest in equal monthly installments over a three-year period until the Options become fully vested on the three (3) year anniversary of the Vesting Start Date. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 22:19 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 167 | $1.72 | $286.74 |
DisclosureSEC source: 0001415889-24-000350 · form4-01032024_100124.xml · nonDerivative · entry 1 Adler Reid G. · CIK 0001924908 · CHF CORP DEVEL OFF, GEN COUNS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,655 F1 · shares: Shares purchased pursuant to the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:05 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 167 | $1.59 | $265.45 |
DisclosureSEC source: 0001415889-23-010720 · form4-07052023_040703.xml · nonDerivative · entry 1 Adler Reid G. · CIK 0001924908 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,488 F1 · shares: Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan ("ESPP"). Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 19:45 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | PurchaseCommon Stock | 300,000 | $0.17 | $50,910.00 |
DisclosureSEC source: 0001415889-22-008894 · form4-08192022_030801.xml · nonDerivative · entry 1 Adler Reid G. · CIK 0001924908 · CHIEF LEGAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,629 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.1689 to $0.1701, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:10 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Options (right to buy) · Derivative | 200,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001415889-22-004542 · form4-05032022_020513.xml · derivative · entry 1 Adler Reid G. · CIK 0001924908 · CHIEF LEGAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-05-02 F1 · derivative.exercise_date: 25% of the stock options vest on May 2, 2023 (the "Vesting Start Date") and 1/36th of the remaining number of shares vest monthly thereafter until all awarded shares are fully vested three (3) years after the Vesting Start Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.